UPLC-MS/MS method for bioequivalence study of oral drugs of meldonium

Biomedical Chromatography

Volumn 26, Issue 5, 2012, Pages 599-605

  Pidpruzhnykov, Yuriy V ^a   Sabko, Valerii E ^a   Iurchenko, Volodymyr V ^a   Zupanets, Igor A ^b  

^a Bioanalytical laboratory Clinfarm   (Ukraine)

^b NATIONAL UNIVERSITY OF PHARMACY   (Ukraine)

Author keywords

Bioequivalence; HILIC; Meldonium; Mildronate; UPLC MS MS

Indexed keywords

COLUMN CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; NUMBER THEORY;

BIOEQUIVALENCE; BIOEQUIVALENCE STUDY; HILIC; HYDROPHILIC INTERACTION CHROMATOGRAPHY; MELDONIA; MILDRONATE; RAPID METHOD; SIMPLE METHOD; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UPLC-MS/MS;

HYDROPHILICITY;

MELDONIUM; MILDRONATE; UNCLASSIFIED DRUG; VASONAT;

ACCURACY; ADULT; ARTICLE; BIOEQUIVALENCE; CALIBRATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG SELECTIVITY; DRUG STABILITY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; HYDROPHILICITY; LIMIT OF QUANTITATION; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA; PRECIPITATION; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 84856565660     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1703     Document Type: Article

References (14)

1. Dambrova M, Liepinsh E and Kalvinsh I. Mildronate: Cardioprotective action through carnitine-lowering effect. Trends in Cardiovascular Medicine 2002; 12: 275-279; doi: 10.1016/S1050-1738(02)00175-5
2. Davies NM, Takemoto JK, Brocks DR and Yáñez JA. Multiple peaking phenomena in pharmacokinetic disposition. Clinical Pharmacokinetics 2010; 49: 351-377; doi: 10.2165/11319320-000000000-00000
3. EMEA/CHMP. Guideline on Validation of Bioanalytical Methods (Draft). EMEA/CHMP/EWP/192217/2009. European Medicines Agency/Committee for Medicinal Products for Human Use, 2009. Available from: (accessed 19 November 2009).
4. FDA/CDER. Guidance for Industry. Bioanalytical Method Validation. Food and Drug Administration/Center for Drug Evaluation and Research, 2001. Available from: (accessed 28 June 2010).
5. Gorbas IM, Barna OM, Sakalosh VU and Bakumenko MA. Evaluation of prevalence and control of risk factors for cardiovascular disease among the population and doctors (Ukrainian). Drugs of Ukraine Plus 2010; 1: 4-9. Available from: (accessed 01 October 2010).
6. Hmelnickis J, Pugovičs O, Kažoka H, Viksna A, Susinskis I and Kokums K. Application of hydrophilic interaction chromatography for simultaneous separation of six impurities of mildronate substance. Journal of Pharmaceutical and Biomedical Analysis 2008; 48: 649-656; doi: 10.1016/j.jpba.2008.06.011
7. Li K, Li W and Huang Y. Determination of free l-carnitine in human seminal plasma by high performance liquid chromatography with pre-column ultraviolet derivatization and its clinical application in male infertility. Clinica Chimica Acta 2007; 378: 159-163; doi: 10.1016/j.cca.2006.11.008
8. Li L, Pabbisetty D, Carvalho P, Avery M, Williamson JS and Avery BA. Ultra-performance liquid chromatography-tandem mass spectrometric method for the determination of Artemisinin in rat serum and its application in pharmacokinetics. Journal of Chromatography B 2008; 867: 131-137; doi: 10.1016/j.jchromb.2008.01.057
9. Lv YF, Hu X and Bi KS. Determination of mildronate in human plasma and urine by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B 2007; 852: 35-39; doi: 10.1016/j.jchromb.2006.12.031
10. Peng Y, Yang J, Wang Z, Wang J, Liu Y, Luo Z and Wen A. Determination of mildronate by LC-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. Journal of Chromatography B 2010; 878: 551-556; doi: 10.1016/j.jchromb.2009.12.030
11. Sjakstea N and Kalvinsh I. Mildronate: an antiischemic drug with multiple indications. Pharmacologyonline 2006; 1: 1-18. Available from:
12. The State Pharmacopoeia of Russian Federation, 12th edn, part 1. Office of the Scientific Center of Expertise of Medical Products, Russian Federation, 2008 (in Russian).
13. Zupanets IA, Bezuglaja NP and Podpruzhnikov YV. The bioequivalence studying of drugs Vazonat and Mildronat: basis of evidence medicine and pharmacy (Ukrainian). Drugs of Ukraine 2009; 5: 72-75. Available from: (accessed 01 August 2009).
14. Zupanets IA, Pidpruzhnykov YV, Golovenko MJ, Bezugla NP and Borisjuk IY. The study of trimethylhydrazinium propionate pharmacokinetic (Ukrainian). Clininal Phamacy 2010; 14: 18-23. Available from: (accessed 01 April 2010).